STAT

The Readout Loud

Business EN ↓ 424 episodes

STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.

Be sure to visit the podcast's website and support the creator: soundcloud.com

Author

STAT

Episodes

Episode 48: The AI hype machine, ketamine's future, and the rocky path ahead for NASH 14.02.2019 23:46

When will AI replace your radiologist? What can pharma learn from ketamine? And is liver disease more complicated than anyone thought?

Episode 47: A bad day for bold biotech, campaign 2020, and where do drugs come from? 07.02.2019 26:27

Are we underestimating biology? Will Hot 97 decide the presidency? And who owns the scientific means of production?

Episode 46: Another Alzheimer's setback, crypto for biotech, and a blessing of unicorns 31.01.2019 24:34

Is the drug industry wrong about Alzheimer's disease? Can cryptocurrency fund actual science? And should you feel sorry for Big Pharma?

Episode 45: CRISPR upheaval, Celgene's chutzpah, and canine genomics 24.01.2019 24:54

Is genome editing harder than anyone thought? Will no one weep for Celgene? And is it time to sequence your dog?

Episode 44: FDA furloughs, '80s pop radio, and video game therapeutics 17.01.2019 23:55

Is the FDA going broke? Can video games be drugs? And when did "Flashdance" come out?

Episode 43: A people's history of J.P. Morgan 10.01.2019 14:45

Do drug developers tip well? Is biotech safe for 6-year-olds? And what's a Cable Car Cosmo?

Episode 42: Parsing Bristol-Myers-Celgene, grousing about JPM, and how to not be boring 03.01.2019 22:05

Are megamergers bad for business? Is it time for biotech's biggest gathering to find a new home? And can a "need" be anything but "unmet"?

Episode 41: Watson's latest stumble, a glimpse into the crystal ball, and revisiting Sarepta 20.12.2018 26:38

What will become of biotech in 2019? What's the legacy of Sarepta Therapeutics? And how do you say "overhyped" in Mandarin?

Episode 40: Gilead’s new boss, the year that was, and the thing about DNA tests 13.12.2018 23:16

Is Gilead Sciences entering a bold new era? What even happened in 2018? And how useful is a genetic credit score?

Episode 39: Using the word 'cure,' an FDA loophole, & making biotech history 06.12.2018 22:45

Can gene therapy cure sickle cell disease? Is an expensive drug better than a free one? And will biotech see its shadow in 2019?

Episode 38: Your guide to the #CRISPRbabies controversy 29.11.2018 23:56

What does it mean to edit a person? Has science run afoul of basic ethics? And what's the time difference to Hong Kong?

Episode 37: The biggest-ever IPO, drug prices rising in tandem, and burner Twitter accounts 15.11.2018 26:17

Can unicorns float? Is a hot dog a sandwich? And how are drug companies like gas stations?

Episode 36: What the midterms mean, a golden age on hold, and the $4 million drug 08.11.2018 22:46

Is pharma in for a swarm of subpoenas? Are we running out of ideas in oncology? And can a drug possibly be worth $4 million a dose?

Episode 35: Biotech's October slump, the precise cost of precision, and breaking postpartum silence 01.11.2018 26:12

Why are biotech stocks in the dumps? Is the latest in cancer care overhyped? And what does "folie à deux" mean?

Episode 34: Pharma at the ballot box, the latest Alzheimer's argument, and a rare disease dilemma 25.10.2018 21:35

Can pharma-shaming get someone re-elected? How rare is too rare when it comes to biotech research? And what does "positive" even mean, really?

Episode 33: Drug prices on TV, immortal blockbusters, and genetic privacy 18.10.2018 24:33

Are prescription drugs like new cars? Is pharma's grand bargain a sham? And who keeps your DNA safe?

Episode 32: Fake friends at the FDA, cancer counter-narratives, and biotech's bear turn 11.10.2018 22:47

Is the next big idea in oncology a bust? What does "successful" mean exactly? And why does Wall Street hate biotech all of a sudden?

Episode 31: Nobel snubs, millenial founders, and a new kind of lightning round 04.10.2018 23:42

Did the Nobel Prizes go to the right scientists? Why is there so much disdain for biotech's millenial entrepreneurs? And do journalists have a good taste in '80s music?

Episode 30: A fish oil epiphany, VC monopolies and ketamine clinics 27.09.2018 25:13

Was everyone wrong about fish oil? Is venture capital a cartel? And what's with all those ketamine clinics?

Episode 29: A Hong Kong heat-check, a $20 million wrist slap, and pharma's (other) diversity problem 20.09.2018 24:38

Is a biotech bubble inflating in China? Do the feds coddle CEOs? And why don't clinical trials look like America?

Episode 28: Founders' funds, doctors' disclosures, and the subtle art of beeping 13.09.2018 22:57

Is biotech too founder-friendly? Is honesty overrated? And how do you tell a good beep from a bad one?

Episode 27: Live from Boston! 06.09.2018 26:08

Should genome editors be worried? Has 2018 been a bummer? And are voters ready to love Big Pharma? We discuss this and more on a special live episode from the BioPharm America conference in Boston.

Episode 26: FDA shows its teeth, biotech fish oil might be pointless, & treating McCain's cancer 30.08.2018 17:57

Is the FDA as lenient as everyone thinks? Can fish oil be a multibillion-dollar drug? And why aren't there better treatments for brain cancer?

Episode 25: A genome-editing first, Trump on Wall Street, and biotech red flags 23.08.2018 21:48

Can genome-editing work in actual people? Are CEOs oversharing? And how do you sniff out a bad bet before it happens?

Episode 24: A lesson in startup jargon, pharma's bare Alzheimer's cupboard, and the cost of CAR-T 16.08.2018 23:52

How much is a shot at curing cancer worth? Where are all the drugs for late-stage Alzheimer's disease? And what on Earth is an "oversubscribed Series A round"?